{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Primary+Open+Angle+Glaucoma+or+Ocular+Hypertension&page=2", "query": { "condition": "Primary Open Angle Glaucoma or Ocular Hypertension", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Primary+Open+Angle+Glaucoma+or+Ocular+Hypertension&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-24T10:46:58.019Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01279083", "title": "Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Open-angle Glaucoma", "Ocular Hypertension" ], "interventions": [ { "name": "DE-112", "type": "DRUG" }, { "name": "DE-112 Vehicle Solution", "type": "DRUG" }, { "name": "Timolol Maleate Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Santen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 147, "start_date": "2011-01", "completion_date": "2012-02", "has_results": false, "last_update_posted_date": "2012-12-17", "last_synced_at": "2026-07-24T10:46:58.019Z", "location_count": 2, "location_summary": "Austin, Texas • San Antonio, Texas", "locations": [ { "city": "Austin", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01279083" }, { "nct_id": "NCT00846989", "title": "Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glaucoma", "Ocular Hypertension" ], "interventions": [ { "name": "RKI983A", "type": "DRUG" }, { "name": "Latanoprost", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 276, "start_date": "2009-01", "completion_date": "2009-04", "has_results": false, "last_update_posted_date": "2020-12-19", "last_synced_at": "2026-07-24T10:46:58.019Z", "location_count": 29, "location_summary": "Artesia, California • Inglewood, California • La Jolla, California + 25 more", "locations": [ { "city": "Artesia", "state": "California" }, { "city": "Inglewood", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Poway", "state": "California" }, { "city": "Stockton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00846989" }, { "nct_id": "NCT04742283", "title": "Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Open Angle Glaucoma", "Ocular Hypertension" ], "interventions": [ { "name": "DE-126 Ophthalmic Solution 0.002% QD", "type": "DRUG" }, { "name": "Timolol Maleate Ophthalmic Solution 0.5% BID", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Santen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 323, "start_date": "2020-12-17", "completion_date": "2021-12-07", "has_results": true, "last_update_posted_date": "2023-06-22", "last_synced_at": "2026-07-24T10:46:58.019Z", "location_count": 41, "location_summary": "Chandler, Arizona • Phoenix, Arizona • Sun City, Arizona + 34 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04742283" }, { "nct_id": "NCT02829996", "title": "Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Open-Angle Glaucoma (POAG)", "Ocular Hypertension (OHT)" ], "interventions": [ { "name": "trabodenoson 6.0% / latanoprost 0.005% QD", "type": "DRUG" }, { "name": "trabodenoson 3.0% / latanoprost 0.005% QD", "type": "DRUG" }, { "name": "trabodenoson 6.0% / latanoprost 0.0025% QD", "type": "DRUG" }, { "name": "latanoprost 0.005% QD", "type": "DRUG" }, { "name": "latanoprost 0.0025% QD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Inotek Pharmaceuticals Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 201, "start_date": "2016-08-19", "completion_date": "2017-05-31", "has_results": true, "last_update_posted_date": "2018-02-15", "last_synced_at": "2026-07-24T10:46:58.019Z", "location_count": 1, "location_summary": "Lexington, Massachusetts", "locations": [ { "city": "Lexington", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02829996" }, { "nct_id": "NCT03896633", "title": "Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glaucoma", "Open Angle or Ocular Hypertension" ], "interventions": [ { "name": "brinzolamide 1% ophthalmic suspension", "type": "DRUG" }, { "name": "Azopt 1%", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bausch & Lomb Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 637, "start_date": "2018-02-28", "completion_date": "2018-11-17", "has_results": true, "last_update_posted_date": "2023-05-09", "last_synced_at": "2026-07-24T10:46:58.019Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03896633" }, { "nct_id": "NCT04284514", "title": "Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ocular Hypertension", "Primary Open Angle Glaucoma" ], "interventions": [ { "name": "AKB-9778 Ophthalmic Solution", "type": "DRUG" }, { "name": "Placebo Ophthalmic Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aerpio Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 91, "start_date": "2019-05-02", "completion_date": "2019-12-15", "has_results": false, "last_update_posted_date": "2020-02-25", "last_synced_at": "2026-07-24T10:46:58.019Z", "location_count": 2, "location_summary": "Austin, Texas • Dallas, Texas", "locations": [ { "city": "Austin", "state": "Texas" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04284514" }, { "nct_id": "NCT00868894", "title": "Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Open-Angle Glaucoma", "Ocular Hypertension" ], "interventions": [ { "name": "DE-104 medium concentration", "type": "DRUG" }, { "name": "DE-104 high concentration", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "0.005% latanoprost", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Santen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2009-03", "completion_date": "2010-06", "has_results": false, "last_update_posted_date": "2011-11-03", "last_synced_at": "2026-07-24T10:46:58.019Z", "location_count": 6, "location_summary": "Artesia, California • Pasadena, California • San Francisco, California + 3 more", "locations": [ { "city": "Artesia", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Kailua", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT00868894" }, { "nct_id": "NCT04944290", "title": "To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Glaucoma, Open-Angle", "Ocular Hypertension" ], "interventions": [ { "name": "Brinzolamide/brimonidine ophthalmic suspension", "type": "DRUG" }, { "name": "Simbrinza 0.2%/1% Ophthalmic Suspension", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Padagis LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 447, "start_date": "2021-05-28", "completion_date": "2022-06-21", "has_results": true, "last_update_posted_date": "2025-04-02", "last_synced_at": "2026-07-24T10:46:58.019Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04944290" }, { "nct_id": "NCT02371746", "title": "Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glaucoma and Ocular Hypertension" ], "interventions": [ { "name": "ENV515-3 Travoprost XR", "type": "DRUG" }, { "name": "ENV515-1 Travoprost XR", "type": "DRUG" }, { "name": "ENV515-3-2 Travoprost XR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Envisia Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 41, "start_date": "2015-01-01", "completion_date": "2019-02-13", "has_results": true, "last_update_posted_date": "2019-10-17", "last_synced_at": "2026-07-24T10:46:58.019Z", "location_count": 14, "location_summary": "Chandler, Arizona • Garden Grove, California • Inglewood, California + 11 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Garden Grove", "state": "California" }, { "city": "Inglewood", "state": "California" }, { "city": "Redding", "state": "California" }, { "city": "Morrow", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02371746" }, { "nct_id": "NCT06865144", "title": "Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Primary Open Angle Glaucoma or Ocular Hypertension" ], "interventions": [ { "name": "Netarsudil ophthalmic solution 0.02%", "type": "DRUG" }, { "name": "Artificial tears", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "East Coast Institute for Research", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2025-06-27", "completion_date": "2026-09-01", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-07-24T10:46:58.019Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06865144" } ] }